On February 4, 2021 F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] reported its financial results for fiscal 2020 (January 1 – December 31, 2020) (Press release, Chugai, FEB 4, 2021, View Source [SID1234574602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche owns 59.89% of Chugai’s outstanding shares (61.17% of the total number of shares issued excluding treasury stock) as of the end of December 2020.

On February 4, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day (Press release, Spectrum Pharmaceuticals, FEB 4, 2021, View Source [SID1234574621]). The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available from the Investor Relations section of the company’s website at View Source with a replay available shortly after the event.

On February 4, 2021 Agendia, Inc., a world leader in precision oncology for breast cancer, reported its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which runs February 17-19, 2021 (Press release, Agendia, FEB 4, 2021, View Source [SID1234574638]). Agendia Chief Executive Officer Mark Straley will participate in a fireside chat discussion on Thursday, February 18 at 11:00 AM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A link to the live webcast of Mr. Straley’s presentation will be available by visiting the News & Updates section of Agendia’s website at View Source A replay of the webcast will be available on the Agendia website for 90 days following the conclusion of the live presentation broadcast.

On February 4, 2021 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported the Company’s Board of Directors has authorized a 10.7% increase in its quarterly dividend from $0.56 to $0.62 per share (Press release, Quest Diagnostics, FEB 4, 2021, View Source [SID1234574656]). The increase is effective with the dividend payable on April 21, 2021 to shareholders of record of Quest Diagnostics common stock on April 7, 2021. With the increase, the annual dividend will be $2.48 per share. This dividend increase is the Company’s tenth since 2011.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, the Board of Directors has increased the Company’s share repurchase authorization by $1 billion. The increased authority is in addition to the $917 million that was available as of December 31, 2020 under the Company’s share repurchase program. For the three months ended December 31, 2020, the Company repurchased 2.0 million shares of its common stock for $250 million.

Quest will hold its quarterly conference call to discuss results for the Fourth Quarter and Full Year 2020 at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The Company suggests participants dial in approximately 10 minutes before the call.

On February 4, 2021 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, reported the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00 per share (Press release, Bolt Biotherapeutics, FEB 4, 2021, View Source [SID1234574677]). In addition, Bolt has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol "BOLT" on February 5, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities are acting as joint bookrunners for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6105 or by email at [email protected].

Registration statements relating to these securities have been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.